Cost-Effectiveness and Budget Impact Analysis of Apatinib for Advanced Metastatic Gastric Cancer from the Perspective of Health Insurance System

Table 3

Summary of the cost and outcome results in base-case analysis.

Strategy	Control (US $)	Apatinib (no PAP)	Apatinib (3 + X)
Cost in disease-free state	529	4215	7868
Cost in disease recurrence state	902	1224	1306
Cost in death for gastric cancer	1033	1076	1149
Total cost ($)	2464	10,323	6515
Disease-free LYs	0.173	0.360	0.360
Overall LYs	0.471	0.750	0.750
QALYs	0.267	0.458	0.458
Incremental cost per LY (US $)		28,170	14,520
Incremental cost per QALY (US $)		40,997	21,132

Compared with the control arm.